Fate Therapeutics Inc (FATE) · Nov 5, 2026 · Earnings
Fate Therapeutics earnings beat as lupus CAR-T trials advance
Beat — EPS $(0.25) vs roughly $(0.29) consensus; revenue $0 vs roughly $1.1M
Fate Therapeutics earnings beat on EPS while RECLAIM-LN and FT839 move forward, backed by a $15 million grant and mid-2028 runway.
Fate Therapeutics is a clinical-stage cell-therapy company trying to turn off-the-shelf, iPSC-derived CAR-T products into a scalable autoimmune platform, with FT819 now in the potentially registrational RECLAIM-LN lupus-nephritis trial and FT839 moving into its broader autoimmune basket study. Its prior quarter had already established first-patient dosing in RECLAIM-LN, FDA clearance for FT839, and a cash runway extending into 2028, so this filing is mainly an execution update rather than a change in direction.
| Q3 2026 | Q3 2025 | Published consensus |
|---|
| Collaboration revenue (Income Statement) | $0 | $1.741M | ~$1.1M |
| Operating expenses (Income Statement) | $32.247M | $36.476M | |
| Net loss (Income Statement) | $30.687M | $32.250M | |
| Diluted loss per share (Income Statement) | $(0.25) | $(0.27) | ~$(0.29) |
| Cash, cash equivalents and investments (Financial Highlights) | $139.1M | | |
The headline financial result was an EPS beat, but not a clean revenue beat. Fate lost $0.25 per share versus published estimates around $0.29, while operating expenses fell year over year; however, collaboration revenue was zero against roughly $1.1 million expected and $1.741 million a year earlier. That makes the quarter modestly better on loss control, not evidence of a commercial revenue inflection. The filing states that “Net loss was $30.7 million, or $(0.25) per share, for the third quarter of 2026.”
The more important business update is that RECLAIM-LN is moving from setup into clinical execution. Enrollment is open at 17 sites, the first patient was treated as an outpatient, and the selected bendamustine regimen produced renal responses in both lupus-nephritis patients with six-month follow-up. That is encouraging for the program’s access and tolerability thesis, but the efficacy sample remains only two patients, so it supports advancement rather than materially de-risking approval. The filing says, “patients with Month 6 follow-up (n=2) achieved a CRR or primary efficacy renal response (PERR).” 〔0〕
FT819’s safety profile is a meaningful positive for the trial design. Across 29 autoimmune patients, there were no dose-limiting toxicities, no ICANS, no graft-versus-host disease, no IEC-HS, and no deaths; CRS was limited to Grade 1–2 in 17.2% of patients. That matters because Fate is positioning a less-intensive, fludarabine-free conditioning regimen as a practical advantage in lupus nephritis, where kidney impairment makes fludarabine less attractive. The filing reports, “No dose-limiting toxicities and no immune effector cell-associated neurotoxicity syndrome (ICANS), no graft-versus-host disease (GvHD), no immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), and no deaths were reported.” 〔1〕
The $15 million CIRM grant improves funding visibility, but does not eliminate financing risk. Cash and investments fell $14.7 million during the quarter to $139.1 million, while management says the grant extends the runway to mid-2028. That is an improvement to the funding story and helps support RECLAIM-LN, but the company remains loss-making, with no recurring product revenue and multiple clinical programs competing for capital. The filing states, “Cash, cash equivalents, and investments of $139.1 million, along with the newly awarded $15.0 million CIRM grant, extends the cash runway to mid-2028.”
FT839 adds a second autoimmune development path, but its near-term value is still executional. Multiple sites are activated and dosing is expected by year-end, giving Fate another clinical catalyst beyond lupus nephritis. The program’s dual CD19/CD38 design and no-conditioning objective are differentiated, but the filing provides no human FT839 efficacy data yet; the immediate test is whether dosing actually begins on schedule.
Bottom line: This was a modestly better-than-expected quarter because loss control, safety data, grant funding, and trial execution all moved in the right direction. The story is advancing, but the core clinical proof remains early and the missing collaboration revenue keeps the financial beat narrow rather than decisive.
What to watch next
ACR Convergence presentations, November 6–11
Original filing on SEC EDGAR
